Core Insights - The FDA has updated the Orange Book to confirm that VOQUEZNA® (vonoprazan) is entitled to a full 10-year period of non-patent New Chemical Entity (NCE) exclusivity, extending through May 3, 2032, which supports the long-term commercial potential of the product [1][2] Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases, with a key product being vonoprazan, marketed as VOQUEZNA® for various GI conditions [3] - VOQUEZNA® is a first-in-class potassium-competitive acid blocker (PCAB) used for the relief of heartburn associated with Non-Erosive GERD and for the treatment of H. pylori infection in adults [3]

Summary of Phathom Pharmaceuticals (PHAT) FY Conference Call - June 11, 2025 Company Overview - **Company**: Phathom Pharmaceuticals - **Product**: AQUESNA, a treatment for acid-related disorders, particularly gastroesophageal reflux disease (GERD) [2][10] Key Points Recent Developments - **Leadership Change**: Steve Fosta joined as CEO a few months prior, focusing on accelerating revenue and product uptake [2][3] - **FDA Approval**: The FDA granted a citizen's petition for exclusivity, allowing Phathom to have exclusivity through 2032, which is a significant development for the company [4][9] Commercial Strategy - **Product Uptake**: AQUESNA is seeing good uptake, with a focus on increasing penetration within the gastroenterology community [2][10] - **Refill Rates**: Patients using AQUESNA report significant improvement, leading to solid refill rates and positive feedback to prescribing physicians [10][11] - **Targeting Gastroenterologists**: The company is shifting focus from primary care to gastroenterologists, as they are expected to adopt the product more quickly due to a higher need among their patients [12][14] Market Coverage - **Insurance Coverage**: Over 80% of commercial lives have coverage for AQUESNA, primarily requiring prior use of PPIs [16][17] - **Medicare and Medicaid**: Coverage is limited, with most Medicare claims being denied; however, a cash pay option is available for patients at $50 per month [19][20] Sales and Marketing - **Sales Strategy**: The company is adjusting its sales strategy to focus more on gastroenterologists, which is expected to yield better results over time [30][32] - **Direct-to-Consumer (DTC) Campaign**: Initial DTC efforts have not shown significant returns yet, but the company believes that deeper adoption within the specialty will eventually lead to increased receptivity to DTC campaigns [33][41] Financial Outlook - **Profitability Timeline**: The company aims to achieve profitability by 2026, with a clear expense target of below $55 million by Q4 2025 [35][75] - **Capital Needs**: Phathom does not anticipate needing to raise additional funds, focusing on reducing operating expenses while ramping up revenue [71][75] Future Opportunities - **Life Cycle Management**: The company is considering expanding indications for AQUESNA, including eosinophilic esophagitis (EOE), and is evaluating the potential for pediatric studies [55][60] - **Pipeline Expansion**: There is interest in exploring new indications, combination products, and in-licensing opportunities to build a robust GI franchise [64][66] Market Trends - **Seasonality**: The company expects typical Q1 softness in sales due to new health plans and deductibles, but anticipates a return to growth in Q2 [22][24] Conclusion - Phathom Pharmaceuticals is strategically positioning itself to enhance the uptake of AQUESNA through targeted marketing and sales efforts, while navigating regulatory landscapes and focusing on profitability in the coming years. The company is optimistic about its growth trajectory and potential market expansion opportunities.

I've been keeping a close eye on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT ) for quite some time. I like what they do; their main focus is on gastrointestinal disorders, and they have a pretty promising drugI’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like ...

Group 1 - Phathom Pharmaceuticals, Inc. (PHAT) shares have increased by 184.1% in the past four weeks, closing at $8.92, with a mean price target of $18.50 indicating a potential upside of 107.4% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $8.09, where the lowest estimate is $5 (44% decline) and the highest is $28 (213.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 16% over the last 30 days, with one estimate increasing and no negative revisions [12] - PHAT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it suggests a positive direction for price movement [13]

Group 1: Block Trades - Kinetik Holdings executed a block trade managed by Goldman Sachs, priced at $44.40 for 4.3 million shares [1] - Pagaya completed a block trade managed by Morgan Stanley, priced at $17.25 for 2.04 million shares [2] - Telus International's block trade was also managed by Morgan Stanley, priced at $2.75 for 3.3 million shares [3] Group 2: IPOs and Secondary Offerings - Circle is preparing for an IPO with multiple managers including JPMorgan, Citi, and Goldman Sachs, priced at $31.00 for 34 million shares [4] - Bitmine Immersion Technologies is conducting a secondary offering managed by ThinkEquity, priced at $8.00 for 2.25 million shares [5] - Cibus is involved in a spot secondary offering managed by Alliance Global Partners, priced at $1.75 for 15.71 million shares [6]

Summary of Phathom Pharmaceuticals (PHAT) Conference Call Company Overview - Phathom Pharmaceuticals is in the early stages of launching a drug that has transformed the reflux market in Japan, now introducing it to the US market as a significant improvement over PPIs, which have been the standard treatment for decades [4][6] - The company reported $28 million in revenue last quarter, projecting a run rate of $120 million annually, with aspirations for the drug to reach a billion-dollar potential [6] Core Business Strategy - The focus is on capturing a significant portion of the reflux patient market, particularly those inadequately treated by PPIs [5] - The company is shifting its sales strategy to concentrate on gastroenterologists (GIs), who are more likely to prescribe the drug compared to primary care physicians (PCPs) [9][10] - Over 50% of prescriptions are already coming from the GI market, indicating a successful initial focus [10] Cost Management and Profitability - Phathom is implementing cost management strategies to achieve profitability by 2026, with a target to reduce operational expenses to $55 million per quarter [11][12] - The company has preserved its sales force, which is crucial for driving revenue, while cutting costs in other areas, including direct-to-consumer (DTC) marketing [17][59] - The DTC campaign is being scaled back due to its ineffectiveness at this stage, with a focus on building relationships with physicians instead [58][59] Market Dynamics and Growth Potential - The company has 82% coverage of commercial lives, with a straightforward prior authorization process for patients who have previously used PPIs [68] - The market for reflux treatments is vast, with no limitations on the total available market, indicating significant growth potential [71] - The company is not currently focused on Medicare coverage but sees opportunities in the commercial insured market [73] Upcoming Challenges and Opportunities - The outcome of the citizens' petition regarding exclusivity for the drug is anticipated soon, which could impact the company's valuation and strategy [79][82] - The company is exploring in-licensing additional GI products to expand its portfolio and leverage existing relationships with gastroenterologists [84][85] Key Takeaways - Phathom Pharmaceuticals is positioned for growth with a breakthrough product in the GI market, focusing on effective sales strategies and cost management to achieve profitability by 2026 [6][12] - The company is adapting its marketing approach to prioritize physician education and advocacy over direct patient advertising, which is seen as premature [58][60] - The potential for additional product launches and the outcome of regulatory petitions will be critical in shaping the company's future trajectory and shareholder value [78][81]

Financial Data and Key Metrics Changes - The preliminary voting results indicate that the nominees for election to the board have been duly elected, and the ratification of Ernst and Young as the company's independent registered public accounting firm has received sufficient votes to be approved [10][11] - The compensation of the named executive officers has received sufficient votes to be approved on an advisory basis, and the frequency of future advisory votes on the compensation of the named executive officers has received sufficient one-year votes to be approved on a nonbinding advisory basis [11] Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were discussed during the meeting [12] Market Data and Key Metrics Changes - No specific market data or metrics were provided during the meeting [12] Company Strategy and Development Direction and Industry Competition - The meeting focused on procedural matters and voting, with no detailed discussion on company strategy or industry competition [9][12] Management's Comments on Operating Environment and Future Outlook - Management did not provide comments on the operating environment or future outlook during the meeting, as there were no stockholder questions addressed [12][13] Other Important Information - The meeting was conducted virtually, and stockholders were informed that any unanswered questions would be addressed on the investor relations section of the corporate website following the meeting [2][12] - The meeting was officially called to order with a quorum present, indicating active participation from stockholders [8][12] Q&A Session Summary Question: Were there any stockholder questions addressed during the meeting? - There were no stockholder questions to be addressed at today's meeting [13]

Financial Data and Key Metrics Changes - The company is in a pivotal phase two/three for ischemic stroke and is simultaneously conducting a phase two study for preeclampsia, with key data expected in the next sixty days [3][34] - The market opportunity for early onset preeclampsia is estimated at about 30,000 patients in the U.S., with a focus on severe cases that require hospitalization [13][14] Business Line Data and Key Metrics Changes - DM199 is a recombinant human tissue kallikrein-1 (KLK1) serine protease enzyme, which has shown potential in increasing perfusion and lowering blood pressure in preeclampsia patients [7][15] - The current treatment options for preeclampsia are described as antiquated and ineffective, highlighting the need for a new therapy like DM199 [14][19] Market Data and Key Metrics Changes - In the U.S., early onset preeclampsia occurs in up to 1% of pregnancies, translating to approximately 40,000 live births annually, indicating a significant market potential for DM199 [13][14] - The company anticipates a high penetration rate for DM199 in the market due to the lack of effective current treatments [13][15] Company Strategy and Development Direction - The company aims to address the unmet need in preeclampsia treatment by providing a therapy that does not cross the placental barrier, thus reducing risks to the fetus [15][19] - The strategy includes leveraging clinical data from existing studies in China to inform the development of DM199 for ischemic stroke and preeclampsia [35][39] Management's Comments on Operating Environment and Future Outlook - Management emphasizes the critical need for effective treatments in preeclampsia, as current medications often fail to manage the disease effectively [19][54] - The company is optimistic about the upcoming data readouts and believes that successful results could validate the efficacy of DM199 in both preeclampsia and ischemic stroke [34][50] Other Important Information - The company is conducting a KOL event on May 28 to discuss the unmet needs in preeclampsia and the design of their clinical trials [58][60] - The pivotal REMEDY two trial for DM199 in acute ischemic stroke is targeting patients who are not eligible for existing treatments, representing a large market opportunity [43][44] Q&A Session Summary Question: Can you discuss the clinical development of DM199 for preeclampsia? - The company is in a pivotal phase two/three for ischemic stroke and simultaneously conducting a phase two study for preeclampsia, with data expected soon [3][34] Question: What is the market opportunity for DM199 in preeclampsia? - The market opportunity is estimated at about 30,000 patients in the U.S., focusing on severe cases that require hospitalization [13][14] Question: Why was South Africa chosen for the preeclampsia trial? - South Africa was selected due to high rates of preeclampsia and the expertise of local investigators in conducting rigorous clinical trials [21][23] Question: What are the key endpoints for the preeclampsia study? - Key endpoints include assessing whether DM199 crosses the placental barrier and its efficacy in lowering blood pressure [30][31] Question: How does DM199 compare to existing treatments for stroke? - DM199 has a 24-hour treatment window, which is significantly longer than existing treatments, potentially allowing more patients to receive effective care [47][49]

Core Insights - Carlyle Group Inc reported a total market value of $3.80 billion for Q1 2025, down from $4.15 billion in the previous quarter, representing an 8% decrease [1][2] - The firm made no new stock purchases, increased its position in one stock, reduced holdings in five stocks, and completely exited four stocks [1][2][5] - The top ten holdings accounted for 99.33% of the total market value [2] Holdings Summary - StandardAero remains the largest holding with approximately 134 million shares valued at about $3.6 billion, making up 92.44% of the portfolio, with a significant increase in shares by 1912.52% [3][4] - Soleno Therapeutics is the second largest holding with around 860,980 shares valued at approximately $61.4 million, representing 1.59% of the portfolio, showing a decrease of 37.41% in shares [3][4] - WeRide (文远知行) holds the third position with about 3.42 million shares valued at approximately $46.5 million, maintaining its share count from the previous quarter [3][4] - Phathom Pharmaceuticals and Pony.ai are the fourth and fifth largest holdings, with values of approximately $21.9 million and $20.8 million, respectively, both maintaining their share counts [3][4] Sell and Exit Activities - Carlyle Group completely exited positions in Ramaco Resources-A, Riley Exploration Permian, Robinhood, and Spyre Therapeutics during the first quarter [3][5] - The top sold stocks included Getty Images, Riley Exploration Permian, Robinhood, Spyre Therapeutics, and Ramaco Resources, with minimal changes in portfolio percentage [5][7]

Core Viewpoint - The appointment of Joseph Hand as General Counsel and Executive Vice President of Operations at Tonix Pharmaceuticals is a strategic move as the company prepares for the potential approval of TNX-102 SL for fibromyalgia management next quarter [1][2]. Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on developing therapies for pain management and vaccines for public health challenges, with a particular emphasis on central nervous system (CNS) disorders [3]. - The company is advancing TNX-102 SL, a product candidate for fibromyalgia management, for which a New Drug Application (NDA) has been submitted based on two statistically significant Phase 3 studies [3]. - The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing authorization for TNX-102 SL, which has also received Fast Track designation [3]. Leadership Experience - Joseph Hand brings over 20 years of strategic legal and business leadership experience in the biopharmaceutical industry, including nearly a decade at Celgene Corporation, where he held senior executive positions [1][2]. - At Celgene, Mr. Hand was involved in significant transactions, including the $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla to Amgen [2]. Strategic Importance - The addition of Mr. Hand is seen as crucial for driving company growth and operational excellence at a pivotal time in Tonix's history, particularly as it prepares for the launch of TNX-102 SL [2]. - The company aims to position itself for long-term growth while delivering meaningful therapies to patients [3]. Development Portfolio - Tonix's development portfolio includes biologics targeting organ transplant rejection, autoimmunity, and cancer, such as TNX-1500, an Fc-modified humanized monoclonal antibody [3]. - The company is also developing a vaccine for mpox, TNX-801, and has secured a contract with the U.S. Department of Defense for up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent [3].